Shaw Peter H, Ritchey Arthur Kim
Department of Pediatrics, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
J Pediatr Hematol Oncol. 2007 Dec;29(12):811-4. doi: 10.1097/MPH.0b013e31815814f3.
Over the last 30 years significant strides have been made in cure rates for children with cancer, but these improvements have not been seen in adolescents and young adults. The reasons for this lack of progress are multifactorial, but it is clear greater cure rates are correlated with controlled clinical trials. Our objective was to see if pediatric patients over the age of 15 had a lower rate of clinical trial enrollment, and if so, why.
We retrospectively analyzed the clinical data on all patients with new oncology diagnoses at Children's Hospital of Pittsburgh (CHP) diagnosed over a 5-year period from July 2001 to June 2006.
Six hundred and forty new oncology patients were seen at CHP over this time, 501 under 15 years old and 139 patients aged 15 to 22. Thirty-six percent of all patients were treated on a clinical trial, including 38% of the younger patients and 27% of the older patients (P=0.03). Fifty-seven percent in the older group were not enrolled on a clinical trial because one was not available versus 41% in the younger group (P=0.04). There were no significant differences between the age groups when other reasons were analyzed.
A significantly lower proportion of adolescents and young adults patients (aged 15 to 22) were placed on a treatment trial than younger patients. The lack of an open clinical trial was the main reason for this deficit. Interventions to address this discrepancy need to be instituted on a national level.
在过去30年里,儿童癌症的治愈率有了显著提高,但青少年和青年成人的治愈率却未见改善。缺乏进展的原因是多方面的,但显然更高的治愈率与对照临床试验相关。我们的目标是了解15岁以上的儿科患者参加临床试验的比例是否较低,若如此,原因何在。
我们回顾性分析了匹兹堡儿童医院(CHP)在2001年7月至2006年6月这5年期间诊断出的所有新发肿瘤患者的临床数据。
在此期间,CHP共诊治了640例新发肿瘤患者,其中501例年龄在15岁以下,139例年龄在15至22岁之间。所有患者中有36%接受了临床试验治疗,其中年龄较小的患者为38%,年龄较大的患者为27%(P = 0.03)。年龄较大组中有57%未参加临床试验是因为没有合适的试验,而年龄较小组这一比例为41%(P = 0.04)。分析其他原因时,各年龄组之间没有显著差异。
与年龄较小的患者相比,青少年和青年成人患者(年龄在15至22岁之间)接受治疗试验的比例明显较低。缺乏开放的临床试验是造成这一差距的主要原因。需要在全国范围内采取干预措施来解决这一差异。